Multiplexed Version of Revolutionary Technology Enables Efficient
Detection of MultipleCancer Mutations in a Single Liquid Assay

Its Ultra High Sensitivity Also Makes Possible the Use of “Liquid
Biopsies” that Allow Oncologiststo Routinely Detect, Monitor and
Tailor Treatments to Evolving Tumor DNA

May 28, 2014 07:00 AM Eastern Daylight Time

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited
diseases through advanced diagnostic tests and clinical and research
services, today announced that it has signed a license with the
Dana-Farber Cancer Institute for worldwide rights to develop and
commercialize multiplexed versions of its ICE COLD-PCRTM
technology (MX ICE COLD-PCR).

The new license is exclusive to Transgenomic and expands the current
relationship with Dana-Farber. It covers all fields and applications of
the multiplexed technology, which makes possible the simultaneous
detection of multiple DNA mutations from a single liquid sample, such as
blood or urine.

Paul Kinnon, President and Chief Executive Officer of Transgenomic
commented, “We believe MX ICE COLD-PCR is a critical enabling technology
that represents a major leap forward in individualized cancer therapy.
For the first time, it will allow comprehensive and affordable tumor
genomic profiling without the need for tumor biopsies, a prerequisite if
ongoing monitoring and optimization of cancer therapy is to become an
everyday reality.”

Mr. Kinnon continued, “Multiplexing makes our ICE COLD-PCR technology
far more efficient and allows us to assemble targeted panels of relevant
mutations that can be simultaneously analyzed from a single sample. This
should greatly increase its availability for routine use in cancer
therapy, as well as for our biopharmaceutical customers who plan to use
MX ICE COLD-PCR to develop new cancer treatments and companion
diagnostics.”

ICE COLD-PCR selectively focuses on only the mutated DNA in tumors that
is useful for cancer diagnosis, monitoring and treatment. It detects
mutated DNA at very high sensitivity—initial validation studies show it
is 100-400 fold more sensitive than conventional approaches. Uniquely,
ICE COLD-PCR also enables identification of all tumor mutations – both
those already known to cancer researchers as well as new mutations not
detected before.

Importantly, the ultra-high sensitivity of ICE COLD-PCR allows DNA
testing to be done using easily accessible samples, such as blood,
plasma and urine, eliminating the need for tumor biopsies, which are
invasive, painful and expensive. By enabling the use of these “liquid
biopsies”, ICE COLD-PCR makes it possible to conduct repeated
assessments of a cancer patient’s disease status both initially and as
treatment proceeds, providing valuable information to help guide
treatment decisions.

ICE COLD-PCR can also analyze DNA from fine needle aspirates,
core-biopsies, or directly from tumors, and it can be used with standard
Sanger sequencing, next generation sequencing, digital PCR and other
technologies, as research in Dr. Mike Makrigiorgos’ lab at Dana-Farber
Cancer Institute has shown.

Transgenomic’s current version of the ICE COLD-PCR technology is also
exclusively licensed from Dana-Farber.

About Transgenomic

Transgenomic,
Inc. is a global biotechnology company advancing personalized
medicine in cardiology, oncology, and inherited diseases through
advanced diagnostic technologies, such as its revolutionary ICE COLD-PCRTM
and its unique genetic tests provided through its Patient Testing
business. The company also provides specialized clinical and research
services to biopharmaceutical companies developing targeted therapies
and sells equipment, reagents and other consumables for applications in
molecular testing and cytogenetics. Transgenomic’s diagnostic
technologies are designed to improve medical diagnoses and patient
outcomes.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements” of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. The known risks,
uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's filings
with the Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such
statements. Accordingly, the Company claims the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release
is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking
statements, unless required by law.